About Jimena Vicencio

Articles by Jimena Vicencio, MD

What is a FISH Test for Multiple Myeloma?
Apr 22, 2024
Understanding Myelofibrosis Prognosis
Apr 22, 2024
When Should I Consider A Clinical Trial For MDS?
Apr 22, 2024
What Is Watch And Wait in MDS?
Apr 17, 2024
Is Myelofibrosis Curable?
Apr 15, 2024
The Critical Steps After MDS Treatment
Apr 15, 2024
What Is The Risk Of Relapse With MDS?
Apr 11, 2024
Hepatitis Treatment as a Possible Therapy for Myeloma Patients?
Apr 11, 2024
What is the Multiple Myeloma Survival Rate?
Apr 09, 2024
How Does Having MDS Change My Daily Life?
Apr 09, 2024
The Role of Transplant in Myelofibrosis
Apr 08, 2024
What Symptoms Indicate Relapse in MDS?
Apr 04, 2024
What Is Secondary Myelofibrosis?
Mar 27, 2024
ASH 2023: Predicting DDX41-Mutant MDS Outcomes Needs a Risk Scoring System
Feb 21, 2024
ASH 2023: Molecular Characteristics of AML and MDS After CT/XRT Exposure
Feb 20, 2024
ASH 2023: Validation of Composite Complete Response Definitions in Higher-Risk Myelodysplastic Syndromes Treated with Hypomethylating Agents: Real-World Analysis
Feb 05, 2024
ASH 2023: Using VALIDATE Database Results to Inform MDS Management
Jan 31, 2024
Potentially Curative Results for AML and High-Risk MDS with CLIA+Venetoclax
Jan 22, 2024
ASH 2023: Understanding Outcomes of CAR T in Extramedullary Multiple Myeloma
Jan 18, 2024
What is Iron Chelation for MDS?
Jan 16, 2024
$Ensayo Clínico: un Nuevo Conjugado Farmacológico de Anticuerpos ANTI-CD38 en el Mieloma Múltiple Recidivante o Refractario image$

Ensayo Clínico: un Nuevo Conjugado Farmacológico de Anticuerpos ANTI-CD38 en el Mieloma Múltiple Recidivante o Refractario
Jan 02, 2024
What You Need To Know About MDS-U, The Type With No Classification
Oct 12, 2023
The Innovation of Myeloma in the 1960s
Sep 14, 2023
What are the different MDS types?
Aug 22, 2023